Apr 02, 2020
Boston Scientific Provides Update on COVID-19 Impact and Response Efforts
Aug 19, 2019
Boston Scientific Closes Acquisition of BTG plc.
Aug 05, 2019
Randomized double-blinded study to commence on DigiFab® for kidney injury related to CABG surgery
Jul 23, 2019
Recommendations for Personalised HCC Treatment With Y90 TheraSphere(TM) Published by an International Multidisciplinary Group
Jul 11, 2019
NCCN issues first pediatric acute lymphoblastic leukemia guidelines, including use of Voraxaze®
Apr 29, 2019
Venous Leg Ulcer Registry Shows Promising Results for Varithena® Use in Wound Healing
Mar 05, 2019
New Research Validates Clinical Value of Treating Copperhead Envenomation with CroFab®
Feb 25, 2019
Boston Scientific Completes $4.3 Billion Offering of Senior Notes and Issues Redemption Notice for its 2020 Notes
Feb 14, 2019
A Retrospective Study of Medicare Claim Data Shows Patients Treated with Voraxaze® had Shorter Hospitalizations and Lower Mortality
Feb 05, 2019
NHS England Expands Loco-regional Treatment Options for Colorectal Cancer Patients With Metastatic Disease [1]
Jan 21, 2019
Australian Patient Treated With DC Bead LUMI(TM), the First Commercially Available Radiopaque Drug-Eluting Bead
Jan 08, 2019
BTG and OMNY Partner to Improve Treatment of Snake Bite Victims
Dec 21, 2018
BTG Announces National Reimbursement for TheraSphere® in France
Dec 20, 2018
Global Interventional Oncology Markets to 2024 - Leading Players are Boston Scientific, Accuray, Medtronic, Terumo, Merit Medical Systems and BTG
Nov 20, 2018
Boston Scientific Announces Recommended Offer to Acquire BTG plc.
Sep 26, 2018
BTG Announces Replacement Policy for Expired CroFab®
Sep 20, 2018
BTG Announces Global Launch of the ICEfx(TM) Cryoablation System
Jun 11, 2018
ELEVATE Study Aims to Improve Selection Criteria and Outcomes for Patients with Severe Emphysema Treated with the PneumRx(TM) Endobronchial Coil System
Apr 04, 2018
SIO and BTG Announce Recipients of Immuno-Oncology/Interventional Oncology Grant Program
Dec 12, 2017
BTG plc: Northwestern University Adopts Y90 TARE with TheraSphere® as First-Line Treatment for HCC